Lars Stenbygaard

1.6k total citations
29 papers, 1.1k citations indexed

About

Lars Stenbygaard is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lars Stenbygaard has authored 29 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 16 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lars Stenbygaard's work include Breast Cancer Treatment Studies (14 papers), Cancer Treatment and Pharmacology (6 papers) and Cancer Diagnosis and Treatment (5 papers). Lars Stenbygaard is often cited by papers focused on Breast Cancer Treatment Studies (14 papers), Cancer Treatment and Pharmacology (6 papers) and Cancer Diagnosis and Treatment (5 papers). Lars Stenbygaard collaborates with scholars based in Denmark, Germany and Norway. Lars Stenbygaard's co-authors include Erik Jakobsen, Marianne Ewertz, Maj‐Britt Jensen, Søren Cold, Dorte Nielsen, Inger Højris, K. Gunnarsdóttir, Ulla Brix Tange, Mette Holck Nielsen and Birgitte Vrou Offersen and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Lars Stenbygaard

29 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lars Stenbygaard Denmark 12 657 516 305 240 177 29 1.1k
K.I. Pritchard Canada 15 682 1.0× 580 1.1× 184 0.6× 182 0.8× 55 0.3× 35 1.1k
F May-Levin France 18 770 1.2× 699 1.4× 138 0.5× 199 0.8× 51 0.3× 43 1.3k
Vieri Scotti Italy 21 764 1.2× 874 1.7× 516 1.7× 85 0.4× 382 2.2× 109 1.6k
Svein Inge Helle Norway 18 429 0.7× 180 0.3× 547 1.8× 203 0.8× 92 0.5× 41 1.1k
Sven‐Börje Ewers Sweden 14 346 0.5× 292 0.6× 255 0.8× 132 0.6× 37 0.2× 27 765
Robert P. Gray United States 15 718 1.1× 859 1.7× 181 0.6× 197 0.8× 23 0.1× 26 1.3k
Georg Stüben Germany 20 488 0.7× 147 0.3× 624 2.0× 193 0.8× 80 0.5× 46 1.2k
Isabelle Birtwisle‐Peyrottes France 13 364 0.6× 308 0.6× 357 1.2× 100 0.4× 87 0.5× 27 711
Barbara Fowble United States 12 550 0.8× 631 1.2× 385 1.3× 126 0.5× 83 0.5× 19 1.4k
David Feltl Czechia 16 529 0.8× 238 0.5× 639 2.1× 100 0.4× 130 0.7× 40 1.1k

Countries citing papers authored by Lars Stenbygaard

Since Specialization
Citations

This map shows the geographic impact of Lars Stenbygaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Stenbygaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Stenbygaard more than expected).

Fields of papers citing papers by Lars Stenbygaard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Stenbygaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Stenbygaard. The network helps show where Lars Stenbygaard may publish in the future.

Co-authorship network of co-authors of Lars Stenbygaard

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Stenbygaard. A scholar is included among the top collaborators of Lars Stenbygaard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Stenbygaard. Lars Stenbygaard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thomsen, Mette S., Jan Alsner, Christina Maria Lutz, et al.. (2024). Breast induration and irradiated volume in the DBCG HYPO trial: The impact of age, smoking, and boost. Radiotherapy and Oncology. 201. 110574–110574. 2 indexed citations
2.
Nielsen, Mette Holck, Lars Stenbygaard, Anders N. Pedersen, et al.. (2024). Benefit of respiratory gating in the Danish Breast Cancer Group partial breast irradiation trial. Radiotherapy and Oncology. 194. 110195–110195. 3 indexed citations
3.
Offersen, Birgitte Vrou, Jan Alsner, Hanne Melgaard Nielsen, et al.. (2022). Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial. Journal of Clinical Oncology. 40(36). 4189–4197. 44 indexed citations
4.
Thorsen, Lise Bech Jellesmark, Jens Overgaard, Martin Berg, et al.. (2022). Internal Mammary Node Irradiation in Patients With Node-Positive Early Breast Cancer: Fifteen-Year Results From the Danish Breast Cancer Group Internal Mammary Node Study. Journal of Clinical Oncology. 40(36). 4198–4206. 38 indexed citations
5.
Offersen, Birgitte Vrou, Jan Alsner, Hanne Melgaard Nielsen, et al.. (2020). Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. Journal of Clinical Oncology. 38(31). 3615–3625. 142 indexed citations
6.
Offersen, Birgitte Vrou, Mette S. Thomsen, Morten Holtegaard Nielsen, et al.. (2017). SP-0315: Partial breast radiotherapy after breast conservation for breast cancer: early results from the randomised DBCG PBI trial. Radiotherapy and Oncology. 123. S163–S164. 4 indexed citations
7.
Offersen, B.V., Morten Holtegaard Nielsen, Martín Krause, et al.. (2017). Hypo- vs normofractionated radiation therapy of early stage breast cancer in the randomized DBCG HYPO trial. European Journal of Cancer. 72. S9–S10. 1 indexed citations
8.
Kamby, Claus, Simon Tarp, Anders Mellemgaard, et al.. (2014). Forebyggelse af skeletrelaterede hændelser hos patienter med knoglemetastaser ved solide tumorer. VBN Forskningsportal (Aalborg Universitet). 176(7). 2–5. 2 indexed citations
9.
Nielsen, Mette Holck, Martin Berg, Anders N. Pedersen, et al.. (2013). Delineation of target volumes and organs at risk in adjuvant radiotherapy of early breast cancer: National guidelines and contouring atlas by the Danish Breast Cancer Cooperative Group. Acta Oncologica. 52(4). 703–710. 146 indexed citations
10.
Fisker, Rune Vincents, Victor Vishwanath Iyer, Torben Fründ, et al.. (2011). MRI and PET/CT of patients with bone metastases from breast carcinoma. European Journal of Radiology. 81(1). e13–e18. 20 indexed citations
11.
12.
Ewertz, Marianne, Maj‐Britt Jensen, K. Gunnarsdóttir, et al.. (2010). Effect of Obesity on Prognosis After Early-Stage Breast Cancer. Journal of Clinical Oncology. 29(1). 25–31. 445 indexed citations
13.
Thomsen, Mette S., Martin Berg, Hanne Melgaard Nielsen, et al.. (2008). Post-mastectomy radiotherapy in Denmark: From 2D to 3D treatment planning guidelines of The Danish Breast Cancer Cooperative Group. Acta Oncologica. 47(4). 654–661. 23 indexed citations
14.
Stenbygaard, Lars & Jan Sørensen. (1999). Small bowel metastases in non-small cell lung cancer. Lung Cancer. 26(2). 95–101. 43 indexed citations
15.
Sørensen, Jonas, Lars Stenbygaard, P Dombernowsky, & Heine H. Hansen. (1999). Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer. Annals of Oncology. 10(9). 1043–1050. 26 indexed citations
16.
17.
Hansen, Flemming, Lars Stenbygaard, & Torben Skovsgaard. (1995). Effect Of Granulocyte-Macrophage Colony-Stimulating Factor (Gm-Csf) On Hematologic Toxicity Induced By High-Dose Chemotherapy In Patients With Metastatic Breast Cancer. Acta Oncologica. 34(7). 919–924. 8 indexed citations
18.
Stenbygaard, Lars, Thomas Christensen, & Claus Kamby. (1995). Elevated Alpha-Feto Protein in a 51-Year-old Male with Relapsing Seminoma, Previous Hepatitis B and Acute Hepatitis C. Acta Oncologica. 34(2). 261–261. 1 indexed citations
19.
Stenbygaard, Lars, et al.. (1993). Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial. Breast Cancer Research and Treatment. 25(1). 57–63. 71 indexed citations
20.
Stenbygaard, Lars, et al.. (1993). Phase II study of 4?-iodo-4?-deoxydoxorubicin in non-resectable non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 32(5). 399–402. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by K.I. Pritchard Breakdown of academic impact, for papers by F May-Levin Breakdown of academic impact, for papers by Vieri Scotti Breakdown of academic impact, for papers by Svein Inge Helle Breakdown of academic impact, for papers by Sven‐Börje Ewers Breakdown of academic impact, for papers by Robert P. Gray Breakdown of academic impact, for papers by Georg Stüben Breakdown of academic impact, for papers by Isabelle Birtwisle‐Peyrottes Breakdown of academic impact, for papers by Barbara Fowble Breakdown of academic impact, for papers by David Feltl
Rankless by CCL
2026